Toxicology Evidence in North Dakota Criminal Cases
A toxicology report can identify or measure alcohol, medications, controlled substances, or other compounds in a biological specimen. It does not…
Blood, urine, vitreous fluid, alcohol, prescription drugs, controlled substances, screening, confirmation, quantitation, chromatography, mass spectrometry, specimen integrity, calibration, controls, uncertainty, pharmacology, impairment, detection windows, retrograde calculations, postmortem redistribution, expert testimony, confrontation, discovery, independent testing, and cross-examination
Toxicology Evidence in North Dakota Criminal Cases
A toxicology report can identify or measure alcohol, medications, controlled substances, or other compounds in a biological specimen. It does not automatically establish impairment, ingestion time, dose, driving-time concentration, causation, or criminal responsibility. Those conclusions require a careful account of the specimen, analytical method, measurement uncertainty, pharmacology, timing, tolerance, interactions, and the facts the expert assumed.
The specimen determines what the result can mean
Whole blood is different from serum or plasma
Forensic blood-alcohol results are commonly reported using whole blood. Hospitals may test serum or plasma, which contain more water and can produce a higher alcohol concentration than whole blood from the same draw. A medical result should not be treated as a forensic whole-blood result without identifying the specimen and any conversion method.
The OSAC alcohol-calculation guidance describes a serum/plasma-to-whole-blood ratio range rather than one universal conversion. The range and resulting uncertainty should be disclosed when a conversion is offered.
Urine usually shows prior exposure, not present blood concentration
Urine collects compounds and metabolites over the period since the last void. Hydration, bladder interval, kidney function, metabolism, and sampling time affect the result. A positive urine result may show prior use without establishing concentration in blood or impairment at a particular moment.
Official OSAC alcohol guidance says urine alcohol is not suited to extrapolation or conversion to a whole-blood equivalent. Drug interpretation should likewise distinguish a urine detection window from active pharmacologic effect.
Vitreous fluid and postmortem specimens have different uses
Vitreous humor, blood from different anatomical sites, urine, tissue, and other fluids may be collected in death investigations. Postmortem decomposition, redistribution, contamination, site, delay, and preservation can change interpretation.
The expert should identify the matrix, collection site, condition, storage, and scientific basis for any conversion or causal conclusion. A postmortem concentration should not be treated as though it came from a living subject under controlled forensic collection.
The North Dakota laboratory accepts several specimen types
The North Dakota Crime Laboratory reports that its biological toxicology section analyzes specimens for alcohol and other volatiles, carboxyhemoglobin, and illicit, prescription, and over-the-counter drugs. Submissions include impaired-driving, death-investigation, and drug-facilitated sexual-assault cases.
The laboratory’s public approved blood-alcohol method identifies blood, urine, vitreous, tissues, biological fluids, and other liquids as possible specimens and describes sodium fluoride and potassium oxalate tubes as preferred for blood.
Collection records establish identity and condition
Obtain the subject’s identity, collector, date and time, collection site, legal authority, tube type, lot and expiration, preservative and anticoagulant, skin preparation, volume, mixing, seal, label, storage, transfer, and laboratory receipt. Compare the report with medical records, body-camera video, kit paperwork, property logs, and laboratory accession.
For hospital draws, determine whether the sample was collected for treatment or law enforcement, what tube was used, how the specimen was handled, and whether the reported test was designed for clinical or forensic purposes.
Preservative and storage affect integrity
Sodium fluoride helps limit microbial activity and glycolysis; an anticoagulant helps prevent clotting. The significance of a missing or expired additive depends on concentration, storage, time, contamination, and the compound measured. Refrigeration or freezing may be appropriate under the laboratory’s method.
Review leakage, broken seals, clotting, headspace, insufficient volume, unusual appearance, temperature, shipment delay, freeze-thaw history, and accession notes. Avoid assuming either that every deviation invalidates the test or that preservatives make condition irrelevant.
Screening, confirmation, and quantitation are different analytical steps
A screening test identifies candidates
Immunoassays and other screens may detect drug classes or selected compounds using cutoffs. Cross-reactivity, sensitivity, specificity, metabolites, and the panel design affect the result. A negative screen does not prove no drug was present outside the panel or below the cutoff.
A presumptive positive should be distinguished from a confirmatory identification. Obtain the assay, lot, cutoff, calibration, controls, cross-reactivity information, instrument output, and reason any screen was not confirmed.
Confirmation uses a more specific method
Gas or liquid chromatography separates compounds; mass spectrometry or another detector helps identify them. Headspace gas chromatography is commonly used for alcohol and volatiles. The method must be validated for the specimen, analyte, concentration range, and intended qualitative or quantitative use.
The North Dakota laboratory’s published accreditation scope lists gas chromatography, immunoassay, liquid chromatography-mass spectrometry, visible spectroscopy, and related technologies for toxicology activities. Accreditation establishes an organizational scope, not that every case-specific result is correct.
Quantitation requires calibration and traceability
A quantitative method compares instrument response with calibrators of known concentration. Review the calibration model, range, standards, traceability, blanks, quality controls, replicate results, dilution, carryover checks, acceptance criteria, and calculations.
A result outside the validated or calibration range may require dilution and repeat analysis. A number with many decimal places should not imply precision beyond the method’s performance.
Internal standards and controls monitor performance
Internal standards can reveal extraction, injection, or instrument variation. Positive and negative controls test whether the method detected what it should and remained free from relevant contamination. Blanks help identify carryover.
Review the entire batch and sequence, not only the accused’s sample. Neighboring high-concentration specimens, reinjections, failed controls, maintenance, column changes, or manual integration can explain an unusual result.
Chromatograms and spectra require interpretation
Retention time, ion ratios, mass spectra, peak shape, signal-to-noise, integration, and reference criteria may support identification and measurement. Interfering compounds, coelution, saturation, background, and software processing can complicate the output.
Request native instrument files, acquisition and processing methods, audit trails, integration history, library searches, calibration data, controls, analyst notes, review, and every reinjection. A printed report does not permit full analytical review.
Limits of detection and quantitation matter
The limit of detection concerns whether a method can reliably distinguish signal from absence under defined conditions. The limit of quantitation concerns measurement performance at low concentration. Laboratories may also use reporting cutoffs.
A “not detected” result can mean below a reporting rule, outside the test panel, degraded, or truly absent. A detected but unquantified compound should not be assigned a precise concentration or pharmacologic effect.
Measurement uncertainty belongs with a quantitative result
No measurement is exact. OSAC’s toxicology uncertainty document addresses bias, calculation, calibration, and reporting components for quantitative measurements.
Ask for the laboratory’s uncertainty budget, coverage factor, confidence level, precision data, bias evaluation, and rule for results near a legal threshold. Measurement uncertainty is different from uncertainty about specimen timing, pharmacology, or impairment; all may matter.
Alcohol interpretation depends on absorption, distribution, elimination, and assumptions
A later blood result is not a direct measurement at the earlier event
The specimen measures concentration at collection. Estimating an earlier concentration requires reliable times and assumptions about whether absorption was complete, drinking continued, elimination rate, distribution, and measurement uncertainty.
Alcohol concentration can be rising, near a peak, or declining. A simple subtraction from a later test is not valid if the person was still absorbing alcohol at the earlier time.
Retrograde calculation should produce a supported range
The OSAC guidance on alcohol calculations states that a person’s exact volume of distribution and elimination rate at a given time cannot be known and cautions experts not to overstate or oversimplify. It recommends a reasonable range with disclosed assumptions rather than a single false-precision value.
Obtain the incident time, last drink, drinking pattern, food, collection time, result, uncertainty, assumed elimination range, absorption assumption, and all calculations. If the history is disputed, calculate supported alternatives instead of treating one account as fact.
Drinking-after-driving and rising concentration require separate analysis
Alcohol consumed after driving can raise a later result without reflecting driving-time concentration. Alcohol consumed shortly before driving may still be absorbing. Receipts, video, witnesses, messages, containers, medical records, and serial tests can affect the reconstruction.
The expert should not select a prosecution-favorable timeline without stating that it came from disputed evidence. A calculation can show what follows from an assumption; it cannot prove the assumption.
Tolerance changes observable effects, not analytical concentration
A tolerant person may display fewer outward signs at a given concentration while still experiencing impairment in divided attention, judgment, or reaction. Conversely, a low concentration does not prove impairment in a particular person.
Expert testimony should distinguish population research, individual variability, observed behavior, and the legal standard. The analyst who measured alcohol may not have the pharmacology training to offer a broad impairment opinion.
Endogenous production and contamination are factual inquiries
Fermentation can occur in some compromised or improperly preserved specimens, particularly postmortem material or samples with microbial contamination. Sodium fluoride, refrigeration, multiple volatiles, specimen comparison, and laboratory patterns may help evaluate the possibility.
The defense should obtain evidence supporting the mechanism rather than suggest fermentation solely because a result is unfavorable. The State likewise should not dismiss integrity questions without examining collection, additives, storage, and analytical indicators.
A positive drug result does not automatically prove impairment
Parent drug and metabolites answer different questions
A parent compound may indicate more recent exposure than an inactive metabolite, but interpretation varies by drug, specimen, dose, route, metabolism, and time. Some metabolites are active; others are not. A laboratory panel may report one without the other.
The expert should identify each compound, whether it is active, what the specimen establishes, and whether concentration-response research supports a case-specific opinion.
Therapeutic, toxic, and fatal ranges overlap
Published concentration ranges are population summaries drawn from different contexts. Tolerance, coingestants, disease, genetics, route, postmortem change, and time affect outcomes. A concentration described as “therapeutic” does not rule out impairment, and a “toxic” range does not prove causation by itself.
Ask what source the expert used, whether it concerns living or postmortem subjects, whole blood or another matrix, single-drug or polydrug cases, and whether the study population resembles the case.
Cannabis presents timing and concentration limits
THC, inactive carboxy-THC, and other cannabinoids have different meanings. Blood concentration changes rapidly after inhalation, while metabolites can remain after acute effects. Frequent users may have residual concentrations. Urine commonly shows prior exposure rather than current impairment.
The expert should avoid converting a single THC result into an exact use time or alcohol-like impairment level without scientific support. Observations, driving, time, specimen type, collection delay, and other evidence remain important.
Prescription drugs require context
Prescribed use does not prevent impairment, and detection does not prove misuse. Dose, timing, formulation, adherence, tolerance, interaction, medical condition, and prescribing instructions affect interpretation. Extended-release and active-metabolite drugs can complicate timing.
Medical and pharmacy records may supply context but also contain hearsay or privacy issues. The toxicologist should identify which facts were assumed and avoid giving a medical diagnosis outside the witness’s field.
Polydrug effects are not simple addition
Alcohol, sedatives, opioids, antihistamines, stimulants, and other compounds can interact additively, synergistically, or antagonistically in observed behavior. The pattern depends on dose, timing, tolerance, and individual response.
A generic statement that substances “can enhance impairment” is different from a supported opinion that they did so in this person at the relevant time. Ask for the concentrations, literature, timing assumptions, and observed signs linked to the conclusion.
Novel substances and broad screens create coverage gaps
A laboratory may not test every synthetic cannabinoid, designer benzodiazepine, novel opioid, or emerging stimulant. Library coverage, reference standards, method validation, and reporting policy change over time.
A negative routine panel does not exclude every intoxicant. A broad high-resolution screen may generate tentative identifications that require confirmation. The report should distinguish confirmed results from library candidates.
Special toxicology issues require separate treatment
Detection windows depend on the analyte and specimen
A detection window is not a fixed property of a drug. It depends on dose, frequency, route, metabolism, specimen, assay sensitivity, reporting cutoff, and whether the laboratory targets a parent compound or metabolite. A compound detectable for days in urine may be measurable for a much shorter period in blood, while hair may reflect a longer historical interval with limited event-level timing.
When a witness gives a use-time estimate, ask for the scientific source, specimen type, concentration, assay cutoff, population, chronic-versus-single use, and confidence range. A broad published window should not become a precise claim that ingestion occurred during the charged event.
Analyte stability is compound specific
Some drugs and metabolites are less stable than others and may degrade through heat, light, pH, enzymes, microbial activity, repeated freeze-thaw cycles, or long storage. Degradation usually lowers a measured concentration, but transformation can sometimes create or increase a measured product. Stability research must match the matrix, container, temperature, concentration, and duration.
Obtain collection and receipt temperatures, refrigerator and freezer logs, shipment records, storage duration, aliquot history, freeze-thaw events, and retest dates. If an independent test differs from the original, timing and stability are part of the comparison rather than automatic proof that one laboratory was wrong.
Enantiomers and isomers can matter
Some analytical methods identify compounds that share a mass or chemical formula without distinguishing structural isomers or mirror-image forms. Methamphetamine, amphetamine, and certain other drugs can have pharmaceutical, illicit, metabolic, or over-the-counter sources that require a more discriminating method for interpretation.
Ask whether the reported method distinguished the relevant isomer or enantiomer, whether that distinction matters to the charge, and whether confirmatory testing remains possible. A chemically accurate broad identification can still be insufficient to establish the source the prosecutor alleges.
Cutoffs are reporting rules, not biological switches
A cutoff may determine whether a laboratory reports a result as positive, negative, detected, or quantifiable. It does not mark the concentration at which every person becomes impaired, and a result immediately below a cutoff is not biologically absent while a result immediately above it is not automatically significant.
The defense should identify whether the cutoff is analytical, administrative, statutory, or interpretive. Ask for the raw response and measurement uncertainty when a reported category sits close to the threshold, subject to the laboratory’s validated range and data policies.
Field and oral-fluid tests have limited purposes
Roadside drug screens, oral-fluid devices, field kits, and preliminary breath instruments may aid investigation or probable-cause decisions. Their specimen, collection, calibration, environmental sensitivity, cross-reactivity, cutoff, and legal status can differ from evidential laboratory testing.
A preliminary result should not be described as a confirmed quantitative toxicology finding. Obtain the device, lot, expiration, operator training, collection adequacy, control check, result display, retention, and confirmatory laboratory work. If the State offers the field result at trial, address relevance, foundation, hearsay, expert interpretation, and unfair-prejudice concerns separately.
Observed signs have competing causes
Red eyes, tremor, confusion, slow speech, rapid speech, poor balance, sweating, elevated pulse, nausea, or unusual behavior can be associated with substances and with fatigue, injury, illness, anxiety, pain, medication, disability, or environmental stress. Toxicology interpretation should not assume every observation was drug caused.
Compare video, standardized examination records, medical findings, baseline information, timing, and the concentrations actually measured. A pharmacologist or clinician may be needed when the opinion moves from analytical detection to medical causation.
Drug-facilitated sexual-assault cases are timing sensitive
Some compounds clear quickly, and delayed collection can produce a negative result despite earlier exposure. Others may be present through lawful medication or voluntary use. Blood and urine have different windows.
Obtain collection time, alleged event time, symptoms, medical treatment, voluntary substances, panel scope, detection limits, specimen storage, and any hair testing. A negative result should not be overstated as proof no drug was administered; a positive result should not prove involuntary administration without context.
Postmortem redistribution can change concentration
After death, drugs can move between tissues and blood, and central and peripheral samples may differ. Decomposition, collection site, delay, embalming, and storage add uncertainty. The expert should identify the specimen location and avoid direct comparison with living therapeutic ranges without qualification.
Carbon monoxide and volatile analysis have distinct methods
Carboxyhemoglobin measures carbon monoxide bound to hemoglobin and may be relevant to fire, vehicle, or death cases. Methanol, isopropanol, acetone, and other volatiles have different metabolic relationships and toxic significance from ethanol.
Ask whether the method separated and quantified each volatile, whether decomposition can produce a compound, and whether clinical treatment altered the result.
Medical testing and forensic testing have different objectives
Clinical laboratories prioritize patient care and may use rapid methods, broad classes, serum, different cutoffs, and medical documentation practices. Forensic laboratories prioritize legal identification, confirmation, chain, and retained records.
A hospital screen can be relevant but should be described accurately. Obtain the hospital’s method, specimen, cutoff, confirmation status, quality records, and witness capable of explaining the test.
Accreditation is not case-specific proof
The North Dakota laboratory is accredited and publishes its scope. Accreditation supports a quality system and competence for listed activities. It does not establish that the correct tube was collected, every control passed, an integration was proper, or the expert’s impairment inference is valid.
The defense should acknowledge the scope accurately while examining the actual records. Overstating accreditation is as unhelpful as ignoring it.
Discovery, expert disclosure, and confrontation shape admissibility
N.D.R.Crim.P. 16(a)(1)(E)–(F) provides for reports of examinations and tests and, after a written request, a summary of prosecution expert opinions, bases and reasons, and qualifications. A final certificate may not disclose the full analytical record or every interpretive opinion.
State v. Doyle, 2024 ND 108, ¶¶ 13–19, reversed where the State failed to provide a required expert summary and the trial court admitted expert testimony without comparing the report to Rule 16’s requirements. Toxicology counsel should make the same line-by-line comparison.
N.D.R.Ev. 707 establishes notice and objection procedures for specified analytical reports, ordinarily requiring prosecution notice sixty days before trial and a defense confrontation objection forty-five days before trial. Counsel should identify the testimonial statement and responsible person, not simply demand every laboratory employee.
Bullcoming v. New Mexico, 564 U.S. 647, 652, 661–65 (2011), rejected admission of a certified blood-alcohol report through a scientist who neither performed nor observed the analysis. Smith v. Arizona, 602 U.S. 779, 789–802 (2024), requires attention to absent-analyst statements used for their truth through another expert.
How defense counsel should investigate toxicology evidence
Build a specimen timeline
Record alleged conduct, stop or incident, last known use, symptoms, medical treatment, collection order, draw, sealing, storage, transfers, laboratory receipt, screening, confirmation, quantitation, review, report, and retained-sample disposition. Reconcile every date and time across police, medical, property, courier, and laboratory records.
Request the complete laboratory file
Seek submission forms, chain, accession, package photographs, specimen condition, methods, validation, calibrators, certificates, controls, blanks, batch and sequence data, chromatograms, spectra, native files, processing methods, integrations, audit trails, calculations, uncertainty, maintenance, quality incidents, proficiency records, analyst notes, review, communications, and remaining specimen.
Retain the right expert
An analytical chemist can evaluate method and data; a forensic toxicologist can address pharmacology and interpretation; a physician may address diagnosis and clinical causation. One witness may not cover every subject. Early consultation can preserve a sample and identify the correct independent test.
Consider independent testing
Determine remaining volume, storage, freeze-thaw history, analyte stability, method, consumption, chain, and whether a split or second tube exists. Independent testing can confirm, refine, or contradict a result, but delay and degradation may affect some compounds.
Separate four opinions in the motion
Analyze identification, concentration, timing, and impairment or causation separately. The laboratory may have a strong identification and measurement while the timing estimate depends on disputed history and the impairment opinion exceeds available research.
Cross-examine from tube to inference
Begin with specimen identity and condition, then screening, confirmation, calibration, controls, uncertainty, analyte meaning, pharmacology, assumptions, timing, and conclusion limits. Use the witness’s own raw data, method, and literature. End with what the result does not establish.
Ask for accurate ranges and wording
Challenge single-number retrograde estimates, unqualified serum conversions, alcohol-like interpretation of drug concentrations, and terms such as “toxic” without population context. A range should disclose assumptions and should not imply the midpoint is most likely unless supported.
Frequently asked questions about toxicology evidence
Does a positive toxicology result prove impairment?
No. Detection and impairment are different. Specimen, concentration, timing, pharmacology, tolerance, interactions, and behavior matter.
What is the difference between screening and confirmation?
Screening identifies possible compounds or classes; confirmation uses a more specific validated method to identify a particular analyte.
Can urine show impairment at a specific time?
Usually not by itself. Urine often reflects prior exposure over the interval since the last void.
Is serum alcohol the same as whole-blood alcohol?
No. Serum or plasma often yields a higher concentration because of water content. Any conversion should use a supported range and disclose uncertainty.
What is measurement uncertainty?
It is a quantified expression of doubt associated with a measurement, based on method performance, calibration, precision, bias, and defined coverage.
What is retrograde extrapolation?
It estimates an earlier alcohol concentration from a later result using time, elimination, absorption, and other assumptions. A supported range is more appropriate than false precision.
Can alcohol concentration still be rising after driving?
Yes. If absorption is incomplete, a later result may be higher than the concentration at the earlier time.
Can prescription medication support an impairment charge?
Potentially, but lawful prescription, dose, timing, tolerance, concentration, interactions, observations, and the governing offense must be evaluated.
Does THC concentration show exact use time?
Generally no. Route, frequency, collection delay, redistribution, and individual variability limit precise timing from one result.
What is an inactive metabolite?
It is a breakdown product that may show prior exposure without producing the parent drug’s pharmacologic effect.
Why do controls matter?
Controls and blanks help detect failed analysis, contamination, carryover, calibration problems, and other batch issues.
Does accreditation prove the test is correct?
No. It supports laboratory competence and a quality system for listed activities, but case-specific collection, analysis, and interpretation still require review.
Can a hospital drug screen be used in court?
It may be relevant, but the specimen, method, cutoff, confirmation status, purpose, records, and witness must be established accurately.
Can the defense retest the sample?
Often yes if sufficient preserved material remains. Counsel should act promptly and document chain, storage, volume, method, and consumption.
What laboratory data should be requested?
Native files, chromatograms, spectra, calibrations, controls, blanks, sequence, integrations, methods, validation, audit trails, uncertainty, review, and quality incidents.
Must the analyst who performed the test testify?
Confrontation depends on the testimonial statements offered for their truth. Bullcoming and Smith restrict substitute testimony about an absent analyst’s case work.
What is North Dakota Rule 707?
It sets notice and objection procedures for specified analytical reports, with ordinary sixty-day and forty-five-day deadlines.
What makes a toxicology challenge effective?
Identify whether the problem concerns specimen integrity, method, measurement, uncertainty, timing, pharmacology, disclosure, confrontation, or an opinion beyond the data.